AtriCure, Inc. (A5I.F)

62,00 0,00 (0,00%) Al cierre: 01:45PM CEST

AtriCure, Inc.

7555 Innovation Way
Mason, OH 45040
United States
513 755 4100
https://www.atricure.com

Sector(es): 
Sector: 
Empleados a tiempo completo: 1200

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Michael H. Carrel	CEO, President & Director	1,87M	N/A	1971
Ms. Angela L. Wirick CPA	Chief Financial Officer	782,83k	N/A	1978
Mr. Douglas J. Seith	Chief Operating Officer	1,12M	N/A	1966
Mr. Salvatore Privitera J.D.	Chief Technical Officer	705,87k	N/A	1967
Mr. Karl S. Dahlquist CCEP, J.D.	Chief Legal Officer	709,2k	N/A	1971
Dr. Vinayak Doraiswamy Ph.D.	Chief Scientific Officer	723,4k	N/A	1972
Valerie Storch-Willhaus	Vice President of Corporate Marketing & Communications	N/A	N/A	N/A
Mr. Justin J. Noznesky	Chief Marketing & Strategy Officer	599,75k	N/A	1978
Ms. Deborah Yount	Chief Human Resources Officer	463,59k	N/A	1966

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Gobierno corporativo

El ISS Governance QualityScore de AtriCure, Inc., a día 1 de mayo de 2024, es 2. Las puntuaciones base son Auditoría: 5; Tablero: 1; Derechos de los accionistas: 3; Compensación: 2.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.